Finally, the recent implementation of EGFR TKIs in multimodality treatment of locally advanced EGFR-mutated lung adenocarcinoma represents a new precision medicine approach which promises to improve outcomes in these patients. This evidence concerns the gene EGFR and lung adenocarcinoma.